2020年12月11日 · Retsevmo is a cancer medicine for use in patients whose cancer is caused by certain changes in a gene called RET, leading to the production of abnormal RET proteins. It can be used for: advanced solid tumours in adults in whom treatments not targeting the RET protein have not worked well enough or who have no other treatment option.

Retsevmo（Selpercatinib，LOXO-292）是一种选择性 RET 激酶抑制剂，用于以下适应症的单药治疗： 晚期 RET 融合阳性的非小细胞肺癌（NSCLC）：适用于需系统性治疗的患者，这些患者之前已接受过基于铂类的化疗和/或免疫治疗。

Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with: – advanced RET fusion-positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate) – advanced RET-mutant medullary thyroid cancer (MTC)

Retsevmo is a cancer medicine for use in patients whose cancer is caused by certain changes in a gene called RET, leading to the production of abnormal RET proteins. It can be used for: . • advanced solid tumours in adults in whom treatments not targeting the RET protein have not worked well enough or who have no other treatment option.

用于治疗RET融合阳性的转移性非小细胞肺癌的成年患者、需要系统性治疗的携带RET突变的晚期或转移性甲状腺髓样癌成人和12岁及以上的儿童患者以及需要系统性治疗和放射性碘治疗（如适用）难治的RET融合阳性的晚期或转移性甲状腺癌成人和12岁及以上的儿童患者。 它由礼来制药研发，信达生物负责中国商业化。

To continue using a Savings Card in 2025, eligible patients can download now under the Savings & Support Page. Now in tablet form with four dose strengths. The first FDA-approved treatment for people with RET -positive advanced non-small cell lung cancer (NSCLC), thyroid cancers, and certain other cancers.

Selpercatinib, sold under the brand name Retevmo among others, is a targeted medication for the treatment of cancers in people whose tumors have an alteration (mutation or fusion) in a specific gene (RET which is short for "rearranged during transfection "). [6][7][9] Before beginning treatment, the identification of a RET gene alteration must b...

Monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis. Optimize blood pressure prior to initiating Retevmo. Monitor blood pressure after 1 week, at least monthly, and as clinically indicated.

2020年5月8日，美国食品药品监督管理局 (FDA)批准了Retevmo (selpercatinib 40毫克、80毫克胶囊)，该药物是首个被批准专门用于治疗转染重排基因 (RET)融合阳性的转移性非小细胞 肺癌 (NSCLC)的成年患者，和需要系统性治疗的携带RET突变的晚期或转移性甲状腺髓样癌成人和12岁及以上的儿童患者，以及需要系统性治疗和放射性碘治疗 (如适用)难治的RET融合阳性的晚期或转移性 甲状腺癌 成人和12岁及以上的儿童患者。 2021年11月9日，中国国家药监局药品审评中 …

RETSEVMO適用於治療需要接受全身性療法且以放射性碘治療無效(若適合接受放射性碘)之晚期或轉移性RET基因融合陽性甲狀腺癌的成人病人。 本適應症係依據整體反應率及反應持續時間獲得加速核准[請見臨床試驗資料(12.3)]。 此適應症仍須執行確認性試驗以證實其臨床效益。 依據腫瘤檢體或血漿檢體是否發現具RET 基因融合(NSCLC 或甲狀腺癌)或特定RET基因突變(MTC), 選擇適合接受RETSEVMO 治療的病人[請見臨床試驗資料(12)]。 (3.1.4)、藥物動力學特性(11)]。 50 kg …